To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 1 mg
NCT ID: NCT00913341
Last Updated: 2017-03-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
1991-11-30
1991-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Demonstrate the Relative Bioavailability of Alprazolam Tablets, 2 mg
NCT00912145
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
NCT00921063
A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety
NCT00139854
A Long-Term Study Continuing on From Study 04-001-01 of an Experimental Medication in Adults With Anxiety Disorder
NCT00106860
Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure
NCT00245609
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
2
Alprazolam Tablets, 1 mg (The Upjohn Company)
Alprazolam Tablets, 1 mg (The Upjohn Company)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)
Alprazolam Tablets, 1 mg (The Upjohn Company)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
19 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niloufar Guiv, M.D.
Role: PRINCIPAL_INVESTIGATOR
PharmaKinetics Laboratories Inc.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9153A
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.